白三烯受体拮抗剂治疗PIF-COPD的临床效果

目的评价白三烯受体拮抗剂治疗慢性阻塞性肺疾病继发肺间质纤维化(PIF-COPD)的临床效果。方法选择收治的96例PIF-COPD患者为研究对象,随机将其分为对照组(n=48)与观察组(n=48)。对照组患者给予祛痰、支气管扩张剂、肺功能锻炼等常规治疗,观察组在常规治疗基础上行白三稀受体拮抗剂治疗。比较两组患者治疗效果。结果治疗后,两组MMRC评分均降低,FVC%、FEV1%及6MWT均显著升高,且观察组优于对照组(P<0.05)。结论白三烯受体拮抗剂治疗PIF-COPD效果显著,值得推广。

Clinical effect of leukotriene receptor antagonist in the treatment of PIF-COPD

Objective To evaluate the clinical effect of leukotriene receptor antagonist in the treatment of chronic obstructive pulmonary disease-pulmonary interstitial fibrosis(PIF-COPD).Methods Ninety-six patients with PIF-COPD admitted in our hospital were selected as study objects.The patients were randomly divided into control group(n=48)and observation group(n=48).The control group was treated with routine treatment such as expectorant,bronchodilator and pulmonary function exercise.The observation group was treated with leukotriene receptor antagonist on the basis of routine treatment.The therapeutic effects of the two groups were compared.Results After treatment,the MMRC scores of the two groups decreased,FVC%,FEV1% and 6MWT of the two groups significantly increased,and those in the observation group were better than the control group(P<0.05).Conclusion Leukotriene receptor antagonist is effective in the treatment of PIF-COPD,which is worthy of promotion.